An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events were between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.

Safety analysis set included all participants who received at least 1 dose of study medication.

Criteria for laboratory test abnormality: Hematology (hemoglobin, hematocrit, red blood corpuscles [RBC] count: less than [<]0.8*lower limit of normal [LLN], platelets: <0.5*LLN/greater than [>]1.75*upper limit of normal [ULN], leukocytes: <0.6*LLN or >1.5*ULN, lymphocytes, total neutrophils: <0.8*LLN or >1.2*ULN, basophils, eosinophil: <0.8*LLN, monocytes: >1.2*ULN); Liver Function (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: >0.3*ULN, total protein, albumin: <0.8*LLN or >1.2*ULN); total bilirubin, direct bilirubin, indirect bilirubin: >1.5*ULN; Renal Function (blood urea nitrogen, creatinine: >1.3*ULN, uric acid: >1.2*ULN); Electrolytes (sodium: <0.95*LLN or >1.05*ULN, potassium, chloride, calcium, bicarbonate: <0.9*LLN or >1.1*ULN; creatine kinase: >2.0*ULN; glucose fasting: <0.6*LLN or >1.5*ULN, urine white blood corpuscles [WBC] and RBC: greater than or equal to (>=) 20/High Power Field [HPF]).

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Criteria for clinically significant vital signs abnormalities included supine/sitting pulse rate of <40 beats per minute (bpm) or >120 bpm, supine systolic blood pressure (SBP) of <90 millimeter of mercury (mmHg), >=30 mmHg maximum increase and decrease from baseline in same posture, supine diastolic blood pressure (DBP) of <50 mmHg; >=20 mmHg maximum increase and decrease from baseline in same posture.

Safety analysis set included all participants who received at least 1 dose of study medication.

Clinically significant ECG findings included PR interval >=300 milliseconds (msec) or >=25 percent (%) increase from baseline (if baseline PR interval >200 msec) or >=50% increase (if baseline PR interval less than or equal to [<=] 200 msec); QRS interval >=140 msec or >=50% increase from baseline; QT interval >=500 msec, corrected QT interval based on Fridericia's formula (QTcF) 450 to <480 msec, 480 to <500 msec, >=500 msec or >=30 msec but <60 msec increase from baseline or >=60 msec increase from baseline.

Safety analysis set included all participants who received at least 1 dose of study medication.

Physical examination included general examination and examination of head, ears, eyes, nose, mouth, throat, neck, abdomen, skin, heart, lungs, lymph nodes, and gastrointestinal and musculoskeletal and neurological system.

Physical examination data reported in this study was for identification of adverse events and were reported as an adverse event in the adverse event section.

Results are reported in micro international units per milliliter (mcIU/mL).

Safety analysis set included all participants who received at least 1 dose of study medication.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who receive at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "N" (number of participants analyzed) signifies those participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "n" signifies those participants who were evaluable for this measure at specified time-points for each arm, respectively.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "n" signifies those participants who were evaluable for this measure at specified time-points for each arm, respectively

Anti-PF-05231023 antibodies and neutralizing antibodies were analyzed only for participants who received PF-05231023 as per planned analysis. One sample at Day 1 was inadvertently tested for neutralizing antibody even though the corresponding anti-PF-05231023 antibody was negative.

Safety Analysis Set included all participants who receive at least 1 dose of study medication. Here "n" signifies those participants who were evaluable for this measure at specified time-points for each arm, respectively

Anti-PF-05231023 antibodies and neutralizing antibodies were analyzed only for participants who received PF-05231023 as per planned analysis. One sample at Day 39 was inadvertently tested for neutralizing antibody even though the corresponding anti-PF-05231023 antibody was negative.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "n" signifies those participants who were evaluable for specified antibodies for each arm, respectively and "N" (number of participants analyzed) signifies participants who were evaluable for this measure.

Safety analysis set included all participants who received at least 1 dose of study medication. Here "n" signifies those participants who were evaluable for specified antibodies for each arm, respectively and "N" (number of participants analyzed) signifies participants who were evaluable for this measure.

AUCtau was calculated for the intact C-terminus and N-terminus PF-05231023 from the concentration-time data using standard non-compartmental method. Only participants who received PF-05231023 were to be analyzed for this outcome measure.

Pharmacokinetic (PK) parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of interest. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.

Tmax was calculated for the intact C-terminus and N-terminus PF-05231023 from the concentration-time data using standard non-compartmental method. Only participants who received PF-05231023 were to be analyzed for this outcome measure.

PK parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of interest.

Cmax was calculated for the intact C-terminus and N-terminus PF-05231023 from the concentration-time data using standard non-compartmental method. Only participants who received PF-05231023 were to be analyzed for this outcome measure.

PK parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of interest.

AUCtau was calculated for the intact C-terminus and N-terminus PF-05231023 from the concentration-time data using standard non-compartmental method. Only participants who received PF-05231023 were to be analyzed for this outcome measure.

PK parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of interest. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.

Tmax was calculated for the intact C-terminus and N-terminus PF-05231023 from the concentration-time data using standard non-compartmental method. Only participants who received PF-05231023 were to be analyzed for this outcome measure.

PK parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of interest. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.

Cmax was calculated for the intact C-terminus and N-terminus PF-05231023 from the concentration-time data using standard non-compartmental method. Only participants who received PF-05231023 were to be analyzed for this outcome measure.

PK parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of interest. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.

Rac was obtained from AUCtau after last dose (Day 22) divided by AUCtau after single dose (Day 1). Rac was calculated for the intact C-terminus and N-terminus PF-05231023 from the concentration-time data using standard non-compartmental method. Only participants who received PF-05231023 were to be analyzed for this outcome measure.

PK parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of interest. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.

Rac was obtained from AUCtau after last dose (Day 22) divided by AUCtau after single dose (Day 1). Rac was calculated for the intact C-terminus and N-terminus PF-05231023 from the concentration-time data using standard non-compartmental method. Only participants who received PF-05231023 were to be analyzed for this outcome measure.

PK parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of interest. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.

Cmin was calculated for the intact C-terminus and N-terminus PF-05231023 from the concentration-time data using standard non-compartmental method. Only participants who received PF-05231023 were to be analyzed for this outcome measure.

PK parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of interest. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.

Cav was calculated for the intact C-terminus and N-terminus PF-05231023 from the concentration-time data using standard non-compartmental method. Only participants who received PF-05231023 were to be analyzed for this outcome measure.

PK parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of interest. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Half-Life was calculated for the intact C-terminus and N-terminus PF-05231023 from the concentration-time data using standard non-compartmental method. Only participants who received PF-05231023 were to be analyzed for this outcome measure.

PK parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of interest. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.

CL is a quantitative measure of the rate at which a drug substance is removed from the body. CL was calculated for the intact C-terminus and N-terminus PF-05231023 from the concentration-time data using standard non-compartmental method. Only participants who received PF-05231023 were to be analyzed for this outcome measure.

PK parameter analysis set included all participants randomized and treated who had at least 1 of the PK parameters of interest. Here "N" (number of participants analyzed) signifies participants who were evaluable for this measure.